Peptron is experiencing a sharp decline of over 10% in early trading on the 30th.
As of 9:20 a.m. on this day, Peptron is trading at 185,000 won, down 20,500 won (10%) from the previous trading day. At one point in early trading, it fell to 160,000 won, but it has somewhat recovered from the decline, maintaining a drop of about 10%.
The decline in Peptron's stock price on this day appears to be influenced by news that British health authorities are investigating acute pancreatitis side effects related to obesity treatments. The British health authorities decided to investigate after a surge in cases of acute pancreatitis following the use of glucagon-like peptide (GLP)-1 obesity treatments.
Peptron is collaborating with Eli Lilly on a 'smart depot' technology that extends the action time of obesity treatments. Eli Lilly, which developed the GLP-1 obesity treatment called Zepbound, is included in the investigation by British health authorities.